The group's principal activities are to discover, develop, manufacture and market products that power the immune system. the group's activities also focus on the development and commercialization of drugs that prevent and treat infectious, autoimmune and addictive diseases. the biopharmaceutical products include nabi-hb tm, winrho sdf, autoplex t tm and aloprim. the antibody products include rho (d) antibodies, hepatitis b antibodies, cmv antibodies, rabies antibodies, tetanus antibodies, diagnostic products and services. antibody products accounted for 69% of 2001 revenues and pharmaceutical products, 31%.